Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an announcement.
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group, released its unaudited financial results for the first half of 2025, showing a decline in revenue and net profit compared to the previous year. Despite a slight increase in total assets, the company experienced a decrease in net assets attributable to shareholders and a reduction in net cash flow from operating activities, indicating challenges in maintaining profitability and operational efficiency.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company has a significant market presence in China and holds a 28.05% equity interest in KPC Pharmaceuticals, Inc., which is listed on the Shanghai Stock Exchange.
Average Trading Volume: 11,247,567
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.05B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money